| Dr Gwenn Marie Mckenzie, MD | |
|
2731 Martin Luther King Blvd, Tuscaloosa, AL 35401-5235 | |
| (205) 758-6647 | |
| (205) 750-2154 |
| Full Name | Dr Gwenn Marie Mckenzie |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 36 Years |
| Location | 2731 Martin Luther King Blvd, Tuscaloosa, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851989610 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 18931 (Alabama) | Secondary |
| 207R00000X | Internal Medicine | MD.18931 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Whatley Health Services Inc | 8224921705 | 25 |
News Archive
With America focused on the future of healthcare, a recent survey provides Americans added confidence in the ability of supplements like MegaRed Omega-3 Krill Oil to support their overall cardiovascular health.
Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy.
Since the outset of our discovery of impurities called nitrosamines in some types of drugs more than two years ago, the U.S. Food and Drug Administration has undertaken a thorough investigation in an effort to protect patients.
Vicor Technologies, Inc. today announced publication of the results of its first clinical study conducted in collaboration with the U.S. Army Institute of Surgical Research (USAISR).
› Verified 4 days ago
| Entity Name | Whatley Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063422756 PECOS PAC ID: 8224921705 Enrollment ID: O20040206000846 |
News Archive
With America focused on the future of healthcare, a recent survey provides Americans added confidence in the ability of supplements like MegaRed Omega-3 Krill Oil to support their overall cardiovascular health.
Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy.
Since the outset of our discovery of impurities called nitrosamines in some types of drugs more than two years ago, the U.S. Food and Drug Administration has undertaken a thorough investigation in an effort to protect patients.
Vicor Technologies, Inc. today announced publication of the results of its first clinical study conducted in collaboration with the U.S. Army Institute of Surgical Research (USAISR).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gwenn Marie Mckenzie, MD 3416 Shamley Dr, Tuscaloosa, AL 35406-2917 Ph: (205) 292-6358 | Dr Gwenn Marie Mckenzie, MD 2731 Martin Luther King Blvd, Tuscaloosa, AL 35401-5235 Ph: (205) 758-6647 |
News Archive
With America focused on the future of healthcare, a recent survey provides Americans added confidence in the ability of supplements like MegaRed Omega-3 Krill Oil to support their overall cardiovascular health.
Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy.
Since the outset of our discovery of impurities called nitrosamines in some types of drugs more than two years ago, the U.S. Food and Drug Administration has undertaken a thorough investigation in an effort to protect patients.
Vicor Technologies, Inc. today announced publication of the results of its first clinical study conducted in collaboration with the U.S. Army Institute of Surgical Research (USAISR).
› Verified 4 days ago
Robert Pieroni, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 850 5th Ave E, Tuscaloosa, AL 35401 Phone: 205-348-1770 Fax: 205-348-5353 | |
Dr. Mark Bruce Nissenbaum, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3701 Loop Rd, Va Medical Center (679/11), Tuscaloosa, AL 35404 Phone: 205-554-2000 Fax: 205-554-2034 | |
Dr. Kyathanahally M. Dinesh Chandra, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 University Blvd E, Suite 711, Tuscaloosa, AL 35401 Phone: 205-345-2255 | |
John Warren, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1100 Ruby Tyler Pkwy, Tuscaloosa, AL 35404 Phone: 205-759-2582 Fax: 205-759-2985 | |
Dr. Neil Kirit Shah, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 850 Peter Bryce Blvd, Tuscaloosa, AL 35401 Phone: 205-348-1770 Fax: 205-348-5145 | |
Bassam Mushannen, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1060 Fairfax Park, Ste B, Tuscaloosa, AL 35406 Phone: 205-758-6471 Fax: 205-758-6472 | |
Michael Shortall, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 3701 Loop Rd, Tuscaloosa, AL 35404 Phone: 205-554-2000 Fax: 205-554-2824 |